Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
- Medijski sadržaj
Blokirali ste korisnika/cu @MsqVentures
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @MsqVentures
-
Ocumension (
#HK ) focuses on#ophthalmology, which#acquired#China rights to a#treatment for acute#blepharitis from France’s Nicox for $13.5M and sales milestones of $11.3M. NCX4251-US#PhaseII trial was#inlicensed from Nicox.#medicaldevice#healthcare#biotech#MSQ#EuropeHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Thanks to everyone who attended the
#Healthcare#Innovation#NYC#Roadshow. Especially thanks to@pwc to co-host the morning#roundtable discussion. Thanks for@PAVmedinc,@Alter_G, TECLens, and PainQx to our afternoon Roadshow session#MSQ#healthcare#investment#china#americapic.twitter.com/f4yVNFMD4z
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
#MSQ will host a#Healthcare#Innovation#NYC#Roadshow on June 20th at 750 Lexington Ave. The event brings together#Chinese healthcare#investors and western companies to generate synergy which will fuel this#wealthy#ecosystem with partnership and#investment.#Biotech#IVDpic.twitter.com/ipUY5j93F1
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Thanks to
@EBDgroup,@echofyang, Founder & CEO at MSQ Ventures is invited to participate in the panel discussion “#investing Today in Tomorrow’s Life-#Transforming#Treatments - Opportunities for#Venture#Capitalists to Move#Science to#Medicine”.#RareDiseaseSummitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Thanks to
@SAPAGP for hosting#RESI#Global#Partnering Conference.@echofyang joined “US-China Bilateral Investment” panel to discuss how to list the business overseas, and#market#access environment in#china, where#Pharmaceutical sector is thriving.#merger#acquisitionpic.twitter.com/WutSBU2Mkc
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Echo Hindle-Yang, CEO at MSQ Ventures, participated as the special guest in the China-US Partnering & Investment Panel,
#Chicago. Generated a wonderful discussion with@GuillaumeVIGNON#biotech companies and#chinese#investors.#Sachs_IOBDLI#investment#immunology#oncologypic.twitter.com/5f80VwZ4WP
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Dr. Mike Zhao, VP at MSQ Ventures just presented at
#biopartnering Forum, Chicago. A variety of great questions and in-depth discussions occurred!@polskycenter@UChicago@guidongzhu#biotech#investment#roadshow#america#china#crossborder#innovation#scientific#msqpic.twitter.com/yXrNfAJ8uu
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
It's traveling time! Our CEO, Echo Hindle-Yang was invited to the 14th Annual World Advanced Therapies & Regenerative Medicine Congress and she joined a panel to discuss current opportunities and limitations in gene therapy.pic.twitter.com/3AFZhsLufl
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Thank you to our special company presenters Christian Cortis, David Liebowitz, Hao Wang, Sam Goldberg,
@notjk and Arif Khan for their deep understanding on blockchain applications in BioTech, Internet, FinTech, Digital Advertising, STO and AI sectors.#MSQ#BlockchainWeekNYCpic.twitter.com/iUPDT3zgaw
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Thank you to our special panelists
@AndreaBonac,@RemingtonOng,@ZhenSpectrum and@huiningcao for their insightful contributions discussing fundamental investment strategies, valuation methodology, business models, outlook, investible ideas and innovation.@TheOnlyMarciano#MSQpic.twitter.com/452IHwKqtn
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Thanks for coming to our Blockchain Summit! We hope our audience enjoyed the relevant and material discussions on regulation, token/ STO/ equity structures, digital asset framework w/
@JTelpner,@BandmanJeff, IBM's David Post, Jay Liang and@ryanwangny.#MSQ#BlockchainWeekNYCpic.twitter.com/K8dis8F8rE
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
We are glad to announce an excellent blockchain summit co-hosted by
@MsqVentures and@CKGSB_America on May 13th, 2019 at 230 Park Avenue, New York. More information available: http://l.ead.me/bb7za7 .#BlockchainWeekNYC#Consensus2019pic.twitter.com/aSwzaopHCP
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
It's our great pleasure to have Andrea on our event. Thanks in advance for his great contribution!
#BlockchainWeekNYC#Consensus2019https://twitter.com/AndreaBonac/status/1125723949822877696 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Cstone will exclusively develop and commercialize ND021 in Greater China, South Korea, and Singapore in exchange of funding the R&D expense of ND021 till the completion of Phase 1b clinical trial.
#commercial#UnitedShades#development#Singapore#Swiss#SouthKorea#ClinicaltrialHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Cstone Pharmaceuticals (China) -focus on the development and commercialization of innovative immuno-oncology/precision medicine, acquired the exclusive rights to Numab(Swiss)’s ND021, a tri-specific antibody which targets PD-L1, 4-1BB, and HSA.
#immunoOncology#China#acquisitionHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
4/29, Luye Pharma in-licensed China rights to PharmaMar’s lurbinectedin (Zepsyre®). The drug is under a phase 3 clinical study in combination with doxorubicin to treat Small Cell Lung Cancer, and it was granted orphan drug designation from FDA.
#Deals#LungCancer#FDA#ophandrugHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
BRAVO!! Happy Anniversary to MSQ!! Thanks
@echofyang and@TheOnlyMarciano for the hard work! Can’t wait for another year’s achievement!#bestteam#Anniversary#WallStreet#China#NewYorkCity#dynamic#MSQ#crossborder#Europe#since2016#value#success#May1stpic.twitter.com/I92AyYFTaA – mjesto: 110 Wall Street
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
BeiGene in-licensed a CTLA-4 inhibitor from BioAtla of San Diego in a $269 million agreement. The two companies will test BA3071 (CAB-CTLA-4) as a monotherapy and in combination with BeiGene's PD-1 candidate, tislelizumab.
#inlicense#Biotechnology#Genetics#healthcare#msqHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Sichuan Haisco will invest $6 M in eXithera, a US Biopharma invested by Israel's Clal Biotechnology Industries. After the deal, Haisco will own 12.5% stake of eXithera and own China rights to a novel anticoagulant.
#biotechnology#Deals#China#US#Israel#biopharmaceuticalHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.